Vertex Pharmaceuticals Incorporated Announced The Us Food And Drug Administration (Fda) Approved Expanded Use Of Orkambi (Lumacaftor/Ivacaftor) To Include Children With Cystic Fibrosis (Cf) Ages 12 To <24 Months Who Are Homozygous For The F508Del Mutation (F/F Genotype) In The Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene. Orkambi Was Previously Approved By The Fda For Use In People With Cf Ages 2 Years And Older With Two Copies Of The F508Del Mutation.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!